Medications called incretin-based therapies, such as GLP-1 receptor agonists, lower systolic blood pressure by about 3.4 mmHg and diastolic blood pressure by about 0.9 mmHg in adults who have overweight or obesity.
See the scientific wording
Incretin-based therapies, including GLP-1 receptor agonists, reduce systolic blood pressure by 3.4 mmHg and diastolic blood pressure by 0.9 mmHg in adults with overweight or obesity.
Strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.
Systematic Review With Meta-AnalysisMeta-analysis2026
This study found that certain weight-loss drugs for people with overweight or obesity also slightly lower blood pressure — just like the claim says. The numbers match exactly, and the drugs didn’t cause dangerous side effects.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Medications called incretin-based therapies, such as GLP-1 receptor agonists, lower systolic blood pressure by about 3.4 mmHg and diastolic blood pressure by about 0.9 mmHg in adults who have overweight or obesity.
Evidence from Studies
Supporting (1)
Community contributions welcome
Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.
This study found that certain weight-loss drugs for people with overweight or obesity also slightly lower blood pressure — just like the claim says. The numbers match exactly, and the drugs didn’t cause dangerous side effects.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists on Blood Pressure in Adults with Overweight or Obesity
Population: Adults with overweight or obesity; Intervention: Incretin-based therapies including GLP-1 receptor agonists; Comparator: Placebo or standard care; Outcome: Change in systolic and diastolic blood pressure; Duration: Minimum 6 months follow-up.
Double-Blind, Placebo-Controlled Trial of Liraglutide on Blood Pressure in Adults with Overweight or Obesity
Population: Adults with overweight or obesity; Intervention: GLP-1 receptor agonist at standard clinical dose; Comparator: Placebo; Outcome: Change in systolic and diastolic blood pressure from baseline to 8 months; Duration: 8 months.
Prospective Cohort Study of Incretin Therapy Use and Blood Pressure Trajectories in Obese Adults
Population: Adults with overweight or obesity initiating incretin-based therapy; Comparator: Adults with similar characteristics not receiving therapy; Outcome: Longitudinal change in systolic and diastolic blood pressure over 8+ months; Duration: Minimum 8 months.
Case-Control Study of Blood Pressure Outcomes in Adults Receiving vs. Not Receiving Incretin-Based Therapies
Population: Adults with overweight or obesity; Cases: Individuals with systolic blood pressure reduction ≥3.4 mmHg; Controls: Individuals with no significant change; Exposure: Prior use of incretin-based therapies; Duration: Retrospective assessment over prior 8 months.
Cross-Sectional Analysis of Blood Pressure and Incretin Therapy Use in Obese Adults
Population: Adults with overweight or obesity; Measurement: Simultaneous assessment of incretin therapy use and blood pressure; Outcome: Cross-sectional correlation between therapy use and blood pressure values.